This inventor holds 10 USPTO granted patents, plus 1 CIPO patent. Top assignees: Wilex Ag, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Wilex Biotechnology Gmbh. Active years: 2005-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Muënchen, DE (2006)
- Pullach, DE (2006 - 2007)
- München, DE (2007 - 2009)
- Munich, DE (2005 - 2010)
Company Filing History:
8 out of 36 
2 out of 1,334 
2 out of 3 Years Active: 2005-2010
Title: The Innovative Contributions of Inventor Stefan Sperl
Introduction
Stefan Sperl, an accomplished inventor based in Munich, Germany, has made significant strides in the field of pharmaceutical innovation. With a total of 10 patents to his name, his work demonstrates a commitment to developing novel therapeutic solutions that address critical health challenges.
Latest Patents
Sperl's latest inventions include groundbreaking compounds aimed at inhibiting the urokinase plasminogen activator (uPA). His patent titled "Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors" presents innovative compounds that offer high bioavailability and oral administerability, which are pivotal for therapeutic applications. These compounds are particularly relevant in the treatment of disorders associated with urokinase and its receptors, including tumors and metastasizing diseases.
Another noteworthy patent is the "Method for the production of phenylalanine derivatives," which outlines an improved technique for synthesizing 3-amidino- or 3-guanidinophenylalanine derivatives. This innovation is especially focused on triisopropylphenyl-sulfonyl-substituted variants, showcasing Sperl's expertise in chemical synthesis and biologically relevant compounds.
Career Highlights
Throughout his career, Stefan Sperl has made meaningful contributions to the field of biotechnology. Notably, he has worked with Wilex AG and Wilex Biotechnology GmbH, where he aimed to advance therapeutic options for various medical conditions. His extensive patent portfolio reflects his dedication to addressing gaps in current treatment methodologies.
Collaborations
Stefan has collaborated with notable professionals in the field, including Luis Moroder and Viktor Magdolen. These partnerships have facilitated the exchange of ideas and have undoubtedly enriched his research endeavors. The synergy between collaborators often leads to breakthroughs that can significantly impact the health sector.
Conclusion
Stefan Sperl's innovative contributions through his patents and collaborative efforts are testaments to his role as a key figure in the pharmaceutical industry. His focus on developing effective therapeutic compounds positions him as a leading inventor dedicated to enhancing healthcare solutions. As he continues to expand his body of work, the potential for impactful advancements remains vast.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile